Replies to post #248684 on Biotech Values

[WorstLuck]

Some commentary from social media:

Never a good sign when a one-product pharma co diversifies into a random cannabis-based topical gel, esp one with a long history of utter trial failures. The timing of the diversification announcement doesn’t strike us as accidental, given our patent challenge and a looming generic catalyst.

$HRMY Harmony Biosciences is now acquiring a microcap $ZYNE that was at -30 cents. Never a good sign when a one-product pharma co diversifies into a random cannabis-based topical gel, esp one with a long history of utter trial failures. The timing of the diversification…

— Scorpion Capital (@ScorpionFund) August 14, 2023